Analysts Set Expectations for KYTX Q3 Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Stock analysts at William Blair issued their Q3 2025 EPS estimates for shares of Kyverna Therapeutics in a report issued on Wednesday, August 20th. William Blair analyst S. Corwin forecasts that the company will earn ($0.99) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share. William Blair also issued estimates for Kyverna Therapeutics’ Q4 2025 earnings at ($1.04) EPS, FY2025 earnings at ($4.04) EPS, FY2026 earnings at ($4.21) EPS and FY2027 earnings at ($3.54) EPS.

Separately, HC Wainwright upgraded shares of Kyverna Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the company from $4.00 to $5.00 in a research note on Tuesday, May 27th. One research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. Based on data from MarketBeat, Kyverna Therapeutics has an average rating of “Buy” and an average price target of $15.60.

Kyverna Therapeutics Stock Performance

Kyverna Therapeutics stock opened at $3.58 on Friday. The firm has a market cap of $154.84 million, a PE ratio of -0.97 and a beta of 3.05. The firm’s 50 day moving average price is $3.44 and its two-hundred day moving average price is $2.80. Kyverna Therapeutics has a twelve month low of $1.78 and a twelve month high of $8.78.

Kyverna Therapeutics (NASDAQ:KYTX) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.03.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Phoenix Wealth Advisors acquired a new position in shares of Kyverna Therapeutics during the 2nd quarter worth $32,000. Catalyst Funds Management Pty Ltd acquired a new position in Kyverna Therapeutics in the 2nd quarter valued at $37,000. Squarepoint Ops LLC acquired a new position in Kyverna Therapeutics in the 4th quarter valued at $43,000. Qube Research & Technologies Ltd acquired a new position in Kyverna Therapeutics in the 2nd quarter valued at $43,000. Finally, Corton Capital Inc. acquired a new position in Kyverna Therapeutics in the 4th quarter valued at $45,000. Institutional investors and hedge funds own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.